Welcome to the Avetix Group YouTube channel.
We were delighted to welcome Dr. Christina Coughlin, CEO of Avacta Therapeutics, onto The BioHub! Avacta are a clinical-stage biotech pioneering next-generation oncology therapies.
In this we cover:
🎙️ Avacta’s pipeline which is often described as “best-in-class” for targeted chemotherapy and peptide-drug conjugates.
🎙️ Avacta currently listed on the London Stock Exchange with the view of looking at NASDAQ.
🎙️ Balancing being a UK Based Biotech with the executive team in the US.
With a remarkable career spanning top pharmaceutical companies and cutting-edge biotech — from Immunocore and Rubius Therapeutics to Tmunity and CytoImmune — Christina brings a unique blend of medical expertise, scientific insight, and leadership acumen. At Avacta, she is driving the development of groundbreaking therapeutics, leveraging proprietary platforms like pre|CISION™, with the goal of bringing life-changing treatments from lab to clinic.
In this episode, we’ll explore her journey from clinician-scientist to biotech executive, the vision and science behind Avacta, and the challenges and opportunities in developing innovative cancer therapies in today’s evolving regulatory and commercial landscape.
